
OSTX Stock Forecast & Price Target
OSTX Analyst Ratings
Bulls say
OS Therapies Inc. is demonstrating strong regulatory momentum for its lead candidate, OST-HER2, now having received an upgraded meeting status from the FDA, indicating alignment toward a potential Accelerated Approval pathway. The company benefits from multiple regulatory designations that may facilitate expedited review, alongside promising clinical data showing statistically significant event-free survival and overall survival in pulmonary metastatic osteosarcoma. Furthermore, the potential for a Priority Review Voucher, valued at approximately $205 million, adds strategic financial value, enhancing the outlook for OS Therapies in the biopharmaceutical market.
Bears say
OS Therapies Inc exhibited a significant increase in operating losses, reporting a loss of $28.75 million in 2025 compared to $8.82 million in 2024, which highlights a troubling trend in cost management as the company expands its development and regulatory efforts. The substantial rise in expenses may strain the company's financial resources and raise concerns about its sustainability in an already challenging clinical stage environment. Furthermore, this elevated cost base could hinder OS Therapies' ability to fund its promising pipeline of treatments for osteosarcoma and other solid tumors, potentially impacting investor confidence and future funding prospects.
This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.
OSTX Analyst Forecast & Price Prediction
Start investing in OSTX
Order type
Buy in
Order amount
Est. shares
0 shares